- Home
- ACFN vs MREO Comparison
ACFN vs MREO Comparison
Compare ACFN & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACFN | MREO |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | United States | United Kingdom |
| Employees | 27 | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.8M | 50.3M |
| IPO Year | 2006 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ACFN | MREO |
|---|---|---|
| Price | $21.11 | $0.29 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 58.0K | ★ 1.2M |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $4,350,000.00 | $500,000.00 |
| Revenue This Year | N/A | $5,184.20 |
| Revenue Next Year | N/A | $55.51 |
| P/E Ratio | $227.06 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.42 | $0.20 |
| 52 Week High | $31.88 | $2.37 |
Technical Indicators
Market Signals| Indicator | ACFN | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 54.63 | 51.30 |
| Support Level | $16.19 | $0.27 |
| Resistance Level | $21.32 | $0.35 |
| Average True Range (ATR) | 1.22 | 0.02 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 63.93 | 81.35 |
Price Performance
Historical ComparisonAbout ACFN Acorn Energy Inc.
Acorn Energy Inc is a holding company that focuses on technology-driven solutions for energy infrastructure asset management. The company operates through two segments namely, the PG segment and the CP segment. PG segment provides wireless remote monitoring and control systems and services for critical assets as well as Internet of Things applications which account for the majority of the revenue. CP segment is engaged in providing remote monitoring of cathodic protection systems on gas pipelines for gas utilities and pipeline companies.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).